Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017130223) A CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO B-CELL MATURATION ANTIGEN, A RECOMBINANT EXPRESSION VECTOR AND A METHOD THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/130223 International Application No.: PCT/IN2017/050040
Publication Date: 03.08.2017 International Filing Date: 28.01.2017
Chapter 2 Demand Filed: 05.12.2017
IPC:
C07K 16/28 (2006.01) ,C07K 14/705 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
Applicants:
MED MANOR ORGANICS, (P) LTD [IN/IN]; #16-11-477/45, Dilsukhnagar, Hyderabad-500 036, IN
Inventors:
BATCHU, Ramesh B.; US
WEAVER, Donald W.; US
PONTES, Jose Edson Silva; US
Agent:
CHADHA & CHADHA; F-46, Himalaya House, 23 K.G. Marg, New Delhi 110001, IN
Priority Data:
20164100342229.01.2016IN
Title (EN) A CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO B-CELL MATURATION ANTIGEN, A RECOMBINANT EXPRESSION VECTOR AND A METHOD THEREOF
(FR) RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE SPÉCIFIQUE D'UN ANTIGÈNE DE MATURATION DES LYMPHOCYTES B, VECTEUR D'EXPRESSION RECOMBINANT ET PROCÉDÉ ASSOCIÉ
Abstract:
(EN) A chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA), a recombinant expression vector and a method for the development of the genetically modified immune effector cells especially natural killer-92 cells (NK-92 cells) that target Multiple Myeloma (MM) and other hematological malignancies. The invention encompasses a single chain variable region (scFv) from BCMA specific antibody fused via transmembrane domain to intracellular signaling domain and two co-stimulatory molecules. Expression of CARs across the plasma membrane of immune effector cells such as natural killer cells (NK cells), NK-92 cells, T lymphocytes (T cells) and natural killer T cells (NKT cells) with exposed scFv interacting with the BCMA tumor target. The interaction initiates cascade of events through the intracellular stimulatory and signaling domains leading to the activation of immune effector cells followed by lysis of the tumor. The invention also includes methods of administering a genetically modified immune effector cells expressing a CAR that comprises a BCMA binding domain.
(FR) La présente invention concerne des récepteurs antigéniques chimériques (CAR) spécifiques d'un antigène de maturation des lymphocytes B (BCMA), un vecteur d'expression recombinant et un procédé de développement des cellules effectrices immunitaires génétiquement modifiées, en particulier des cellules NK-92 (cellules tueuses naturelles-92) qui ciblent le myélome multiple (MM) et d'autres tumeurs malignes hématologiques. L'invention concerne une région variable monocaténaire (scFv) d'un anticorps spécifique de BCMA fusionné par un domaine transmembranaire à un domaine de signalisation intracellulaire et deux molécules costimulatrices. L'invention concerne également l'expression de CAR à travers la membrane plasmique de cellules immunitaires effectrices telles que des cellules NK (tueuses naturelles), des cellules NK -92, des lymphocytes T (cellules T) et des lymphocytes T tueurs naturels (cellules NKT) avec scFv exposée interagissant avec la cible tumorale BCMA. L'interaction déclenche une cascade d'événements à travers les domaines de stimulation et de signalisation intracellulaire, conduisant à l'activation des cellules immunitaires effectrices suivie de la lyse tumorale. Cette invention concerne en outre des procédés d'administration de cellules immunitaires effectrices génétiquement modifiées exprimant un CAR qui comprend un domaine de liaison de BCMA.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3408297